… or L858R mutations, 77 patients were treated with gefitinib or erlotinib according to their
physician’s discretion and were included in this study. The remaining 67 patients were either not …

… Patients and Methods: We retrospectively studied gefitinib-resistant NSCLC … We retrospectively
studied gefitinib-resistant NSCLC p atients treated with erlotinib after long periods of SD. …

… The objective of the study was to observe the efficacy and safety of pulsatile administration
of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (…

… patients with lung adenocarcinoma (stage IIIb/IV), who had progressed after chemotherapy
(1–2 lines) and at least 12 weeks of erlotinib or gefitinib… reported from this study, in addition to …

… Study subjects and data collection This study included 599 patients with EGFR-mutant
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …

… patients enrolled on clinical trials of agents to treat acquired resistance to erlotinib or gefitinib…
However, in this study there was not a lower rate of disease flare in patients with T790M-…

… This study analyzed 95 patients enrolled in EURTAC trial for T790M end P53 mutations,
EML4-ALK translocation and BIM mRNA expression levels. The results showed that OS for …

… I studies of gefitinib and erlotinib were performed in patients … , phase II studies with gefitinib
or erlotinib in patients with … Gefitinib was studied in two multicenter trials: the Iressa ® Dose …

… ) is comparable between gefitinib and erlotinib for treating East Asian patients with NSCLC.
… that an increasing number of studies have used gefitinib and erlotinib as first-line treatment …

… After screening, 40 studies involving 9376 patients (5602 patients in the gefitinib group
and 3774 patients in the erlotinib group) were included for the final analysis (Fig. 1). [6,8–13,17–…